Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Antigenic fractions of Leishmania (Viannia) braziliensis: the immune response characterization of patients at the initial phase of disease.

Brelaz MC, de Oliveira AP, de Almeida AF, de Assis Souza M, Medeiros ÂC, de Brito ME, Pereira VR.

Parasite Immunol. 2012 Apr;34(4):236-9. doi: 10.1111/j.1365-3024.2012.01351.x.

2.

Cellular immune response evaluation of cutaneous leishmaniasis patients cells stimulated with Leishmania (Viannia) braziliensis antigenic fractions before and after clinical cure.

Brelaz-de-Castro MC, de Almeida AF, de Oliveira AP, de Assis-Souza M, da Rocha LF, Pereira VR.

Cell Immunol. 2012 Oct;279(2):180-6. doi: 10.1016/j.cellimm.2012.11.006. Epub 2012 Nov 29.

3.

T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure.

Coutinho SG, Oliveira MP, Da-Cruz AM, De Luca PM, Mendonça SC, Bertho AL, Soong L, McMahon-Pratt D.

Exp Parasitol. 1996 Nov;84(2):144-55.

PMID:
8932764
4.

Differential effects of antigens from L. braziliensis isolates from disseminated and cutaneous leishmaniasis on in vitro cytokine production.

Leopoldo PT, Machado PR, Almeida RP, Schriefer A, Giudice A, de Jesus AR, Ho JL, Guimarães LH, Bacellar O, Carvalho EM.

BMC Infect Dis. 2006 Apr 25;6:75.

5.

Multifunctional CD4⁺ T cells in patients with American cutaneous leishmaniasis.

Macedo AB, Sánchez-Arcila JC, Schubach AO, Mendonça SC, Marins-Dos-Santos A, de Fatima Madeira M, Gagini T, Pimentel MI, De Luca PM.

Clin Exp Immunol. 2012 Mar;167(3):505-13. doi: 10.1111/j.1365-2249.2011.04536.x.

6.

Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis.

Bottrel RL, Dutra WO, Martins FA, Gontijo B, Carvalho E, Barral-Netto M, Barral A, Almeida RP, Mayrink W, Locksley R, Gollob KJ.

Infect Immun. 2001 May;69(5):3232-9.

7.

T-cell responses associated with resistance to Leishmania infection in individuals from endemic areas for Leishmania (Viannia) braziliensis.

Bittar RC, Nogueira RS, Vieira-Gonçalves R, Pinho-Ribeiro V, Mattos MS, Oliveira-Neto MP, Coutinho SG, Da-Cruz AM.

Mem Inst Oswaldo Cruz. 2007 Aug;102(5):625-30.

8.

Cellular immune response profile in patients with American tegumentary leishmaniasis prior and post chemotherapy treatment.

Reis LC, Brito ME, Souza MA, Medeiros AC, Silva CJ, Luna CF, Pereira VR.

J Clin Lab Anal. 2009;23(1):63-9. doi: 10.1002/jcla.20291.

PMID:
19140214
9.

Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production.

Castellano LR, Filho DC, Argiro L, Dessein H, Prata A, Dessein A, Rodrigues V.

Hum Immunol. 2009 Jun;70(6):383-90. doi: 10.1016/j.humimm.2009.01.007. Epub 2009 Jan 20.

PMID:
19480861
10.

Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?

Gomes-Silva A, de Cássia Bittar R, Dos Santos Nogueira R, Amato VS, da Silva Mattos M, Oliveira-Neto MP, Coutinho SG, Da-Cruz AM.

Clin Exp Immunol. 2007 Sep;149(3):440-4. Epub 2007 Jul 5.

11.

A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.

Skeiky YA, Guderian JA, Benson DR, Bacelar O, Carvalho EM, Kubin M, Badaro R, Trinchieri G, Reed SG.

J Exp Med. 1995 Apr 1;181(4):1527-37.

12.

Immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis.

Silveira FT, Lainson R, De Castro Gomes CM, Laurenti MD, Corbett CE.

Parasite Immunol. 2009 Aug;31(8):423-31. doi: 10.1111/j.1365-3024.2009.01116.x. Review.

13.

Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry.

Berner B, Akça D, Jung T, Muller GA, Reuss-Borst MA.

J Rheumatol. 2000 May;27(5):1128-35.

PMID:
10813277
14.

Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis.

Salhi A, Rodrigues V Jr, Santoro F, Dessein H, Romano A, Castellano LR, Sertorio M, Rafati S, Chevillard C, Prata A, Alcaïs A, Argiro L, Dessein A.

J Immunol. 2008 May 1;180(9):6139-48.

15.

Deletion of IL-4Ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection.

Radwanska M, Cutler AJ, Hoving JC, Magez S, Holscher C, Bohms A, Arendse B, Kirsch R, Hunig T, Alexander J, Kaye P, Brombacher F.

PLoS Pathog. 2007 May 11;3(5):e68.

16.

Immunopathological characterization of human cutaneous leishmaniasis lesions caused by Leishmania (Viannia) spp. in Amazonian Brazil.

Castro Gomes CM, Sousa MGT, Menezes JPB, Batista MC, Lima ACS, Belda W Jr, Bradshaw D, Gama MEA, Laurenti MD, Silveira FT, Corbett CEP.

Parasitol Res. 2017 May;116(5):1423-1431. doi: 10.1007/s00436-017-5403-4. Epub 2017 Feb 21.

PMID:
28224222
17.

The skin homing receptor cutaneous leucocyte-associated antigen (CLA) is up-regulated by Leishmania antigens in T lymphocytes during active cutaneous leishmaniasis.

Mendes-Aguiar Cde O, Gomes-Silva A, Nunes E Jr, Pereira-Carvalho R, Nogueira RS, Oliveira-Neto Mde P, Bertho AL, Da-Cruz AM.

Clin Exp Immunol. 2009 Sep;157(3):377-84. doi: 10.1111/j.1365-2249.2009.03970.x.

18.

Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil.

Romero GA, de la Glória Orge Orge M, de Farias Guerra MV, Paes MG, de Oliveira Macêdo V, de Carvalho EM.

Acta Trop. 2005 Jan;93(1):49-56.

PMID:
15589797
19.

Leishmania-reactive CD4+ and CD8+ T cells associated with cure of human cutaneous leishmaniasis.

Da-Cruz AM, Conceição-Silva F, Bertho AL, Coutinho SG.

Infect Immun. 1994 Jun;62(6):2614-8.

20.

T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy.

Da-Cruz AM, Bittar R, Mattos M, Oliveira-Neto MP, Nogueira R, Pinho-Ribeiro V, Azeredo-Coutinho RB, Coutinho SG.

Clin Diagn Lab Immunol. 2002 Mar;9(2):251-6.

Supplemental Content

Support Center